|DiaGenic Announces Promising Early Results from R&D Project with Pfizer; K-V Pharma Shares Higher on Medical Group Comments.|
|By Staff and Wire Reports|
|Friday, 14 October 2011 18:23|
DiaGenic ASA announced that the Company has reported preliminary positive findings from the collaborative Research and Development (R&D) project with Pfizer Inc. (NYSE:PFE) where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring of Alzheimer's Disease (AD).
The study cohort consisted of a total of 120 subjects, including healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD.
Baseline and two-year longitudinal samples from DiaGenic's clinical multicenter studies and biobank were used for the study.
Shares of K-V Pharmaceuticals (NYSE:KV.A) continued to trade higher Friday morning a day after a doctors’ group clarified that the company’s Makena birth drug isn’t identical to lower-cost versions of the drug.
The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine said in a joint statement that physicians should understand the “inherent differences” between Makena, which has Food and Drug Administration approval, and drugs made using compounding processes.
“Healthcare providers understand that evidence-based medicine is the foundation of clinical practice,” K-V Pharmaceuticals said in a statement. “Access to FDA-approved Makena for clinically-indicated patients is an important public health priority.”
Evidence from a study that supported the use of one of Makena's compounds, known as 17P, was based on Makena rather than a drug obtained from compounding pharmacies, the groups said. Certain payer coverage policies had been influenced by a false belief that the unapproved lower-cost drugs are the same as Makena.
ACCESS PHARMACEUTICALS, INC.(OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,has updated its MuGard website to include a clinical feedback video.
Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011. The dividend will be paid on Dec. 8, 2011 to all stockholders of record as of the close of business on Nov. 17, 2011.
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, will present at the 18th Annual NewsMakers in the Biotech Industry conference on Friday, October 21st in New York.
Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Robert A. Bradway to the Company's Board. Bradway, 48, is Amgen's president and chief operating officer.
Capsalus Corp.(OTCBB:WELL), a public company operating in the health and wellness space, has finalized the definitive agreement with leading biosciences company GeneLink Biosciences, Inc. (OTCBB:GNLK) to acquire 100% of the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc., pending GeneLink shareholder approval and other related terms.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at the BioCentury NewsMakers in the Biotech Industry Conference onFriday, October 21st, at 2:00 p.m. EDT in New York City.
China Cord Blood Corporation (NYSE: CO), the first and largest cord blood banking operator in China, today announced that the Company will hold its annual general meeting of shareholders at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 19, 2011 (8:00 a.m. U.S. Eastern Time on December 19, 2011).
Columbia Laboratories Inc. (Nasdaq: CBRX) announced today that Lawrence A. Gyenes, Senior Vice President, Chief Financial Officer and Treasurer will present at the 18th Annual NewsMakers in the Biotech Industry Conference.
GeneLink Biosciences, Inc. (OTCBB:GNLK), a leading consumer genomics biotech company, has finalized a definitive agreement with Capsalus Corp. (OTCBB:WELL), a public company operating in the health and wellness space, to sell the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc., pending GeneLink shareholder approval and other related terms.
Health Discovery Corporation (OTCBB: HDVY) today announced its agreement with the U.S. Preventive Services Task Force’s (USPSTF) stance against the use of the prostate-specific antigen (PSA), a test used by 90 percent of U.S. men to screen for prostate cancer.
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trial for ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces an update to its previously announced agreement with Baxter Healthcare Corporation for the joint development of the Factor VIII Biopump which expired on September 30, 2011.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected DNAA, Inc. to serve as the exclusive distributor in Panama for its Nyloxin-branded pain relievers.
ShangPharma Corporation (NYSE: SHP), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong today.
VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference.
ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that Ms. Wenjuan Xiao, a member of the board of directors of the Company, has resigned from the board, effective October 13, 2011.
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of Abgent, Inc., a provider of biological research reagent products and services based in Suzhou, China, and San Diego, California.
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the BioCentury Newsmakers in the Biotech Industry Conference on Friday, October 21st, 2011, at 1:30 pm Eastern Time, at The Millennium Broadway Hotel & Conference Center in New York City.